Fed. Circ. Upholds GSK Win Over Avodart Patent

Law360, New York (February 24, 2014, 4:49 PM EST) -- The Federal Circuit on Monday upheld a Delaware district court's ruling that Banner Pharmacaps Inc., Mylan Pharmaceuticals Inc. and other generic-drug makers failed to prove that a patent owned by British pharmaceutical company GlaxoSmithKline LLC for the prostate reduction pill Avodart was invalid. 

The three-judge panel rejected arguments by Banner, Mylan, Roxane Laboratories Inc., Watson Laboratories Inc. and Impax Laboratories Inc. that U.S. Patent Number 5,565,467 failed to adequately describe a chemical compound known as a “solvate” in dutasteride, the generic name for the Avodart drug....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

GlaxoSmithKline LLC v. Banner Pharmacaps, Inc.


Case Number

13-1593

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

August 29, 2013


Case Title

GlaxoSmithKline LLC v. Banner Pharmacaps, Inc.


Case Number

13-1594

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

August 29, 2013


Case Title

GlaxoSmithKline LLC v. Banner Pharmacaps, Inc.


Case Number

13-1595

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

August 29, 2013


Case Title

GlaxoSmithKline LLC v. Banner Pharmacaps, Inc.


Case Number

13-1598

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

August 30, 2013

Law Firms

Companies

Government Agencies

Patents

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.